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Background: COVID-19 pandemic has developed rapidly and the ability to stratify the most 
vulnerable patients is vital. However, routinely used severity scoring systems are often low on 
diagnosis, even in non-survivors. Therefore, clinical prediction models for mortality are 
urgently required.  
Methods: We developed and internally validated a multivariable logistic regression model to 
predict inpatient mortality in COVID-19 positive patients using data collected retrospectively 
from Tongji Hospital, Wuhan (299 patients). External validation was conducted using a 
retrospective cohort from Jinyintan Hospital, Wuhan (145 patients). Nine variables commonly 
measured in these acute settings were considered for model development, including age, 
biomarkers and comorbidities. Backwards stepwise selection and bootstrap resampling were 
used for model development and internal validation. We assessed discrimination via the C 
statistic, and calibration using calibration-in-the-large, calibration slopes and plots. 
Findings: The final model included age, lymphocyte count, lactate dehydrogenase and SpO2 
as independent predictors of mortality. Discrimination of the model was excellent in both 
internal (c=0·89) and external (c=0·98) validation. Internal calibration was excellent 
(calibration slope=1). External validation showed some over-prediction of risk in low-risk 
individuals and under-prediction of risk in high-risk individuals prior to recalibration. 
Recalibration of the intercept and slope led to excellent performance of the model in 
independent data.  
Interpretation: COVID-19 is a new disease and behaves differently from common critical 
illnesses. This study provides a new prediction model to identify patients with lethal COVID-
19. Its practical reliance on commonly available parameters should improve usage of limited 
healthcare resources and patient survival rate.   
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Research in context 
 
Evidence before this study 
Since the outbreak of COVID-19, there has been a pressing need for development of a 
prognostic tool that is easy for clinicians to use. Recently, a Lancet publication showed that in 
a cohort of 191 patients with COVID-19, age, SOFA score and D-dimer measurements were 
associated with mortality. No other publication involving prognostic factors or models has been 
identified to date.   
Added value of this study 
In our cohorts of 444 patients from two hospitals, SOFA scores were low in the majority of 
patients on admission. The relevance of D-dimer could not be verified, as it is not included in 
routine laboratory tests. In this study, we have established a multivariable clinical prediction 
model using a development cohort of 299 patients from one hospital. After backwards selection, 
four variables, including age, lymphocyte count, lactate dehydrogenase and SpO2 remained in 
the model to predict mortality. This has been validated internally and externally with a cohort 
of 145 patients from a different hospital. Discrimination of the model was excellent in both 
internal (c=0·89) and external (c=0·98) validation. Calibration plots showed excellent 
agreement between predicted and observed probabilities of mortality after recalibration of the 
model to account for underlying differences in the risk profile of the datasets. This 
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demonstrated that the model is able to make reliable predictions in patients from different 
hospitals. In addition, these variables agree with pathological mechanisms and the model is 
easy to use in all types of clinical settings.  
Implication of all the available evidence 
After further external validation in different countries the model will enable better risk 
stratification and more targeted management of patients with COVID-19. With the nomogram, 
this model that is based on readily available parameters can help clinicians to stratify COVID-




 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
(which was not peer-reviewed) The copyright holder for this preprint .https://doi.org/10.1101/2020.03.28.20045997doi: medRxiv preprint 
 5 
Introduction 
Since the outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in China, there 
have been over 200,000 confirmed cases, with 10-20% developing severe COVID-19 and 
approximately 5% requiring intensive care1,2. Although the number of daily cases has 
significantly reduced in China because of intensive control procedures, the numbers in the rest 
of world are continuing to increase. More than 10,000 deaths have been reported but the 
estimated mortality rate (3%) is much lower than Severe Acute Respiratory Syndrome (SARS) 
in 2003 (9·6%, 774 died of 8096 infected) and Middle East Respiratory Syndrome (MERS) in 
2012 (34·4%, 858 died of 2494 infected)3. Although the vast majority of cases of COVID-19 
are not life-threatening, stratification of these patients becomes increasingly important as large 
populations are expected to be infected globally.  
The deaths and morbidity from COVID-19 infection are primarily due to respiratory failure, 
although a few people have died of multiple organ failure (MOF) or chronic comorbidities4,5. 
Therefore, reduced oxygen saturation is the major indicator of disease severity. However, 
symptoms at onset are relatively mild and a substantial proportion of patients have no obvious 
symptoms prior to the development of respiratory failure4,5. Clinically, it is difficult to stratify 
patients who may develop lethal COVID-19 until respiratory failure develops. Since early 
identification and effective treatment can reduce mortality and morbidity as well as relieve 
resource shortages, there is an urgent need for effective prediction models to identify patients 
who are most likely to develop respiratory failure and poor outcomes.  
A robust, highly discriminatory and validated clinical prognosis model is required for 
stratification of these patients. Currently, very few reports propose reliable prediction models, 
which have been constructed using Transparent Reporting of a multivariable prediction model 
for Individual Prognosis Or Diagnosis (TRIPOD) guidance with internal and external 
validation6. One report based on a cohort of 191 COVID patients in early stages of the 
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pandemic showed that age, Sequential Organ Failure Assessment (SOFA) score and D-dimer 
are independent risk factors of mortality7. However, D-dimer is not a routinely available 
clinical measurement and SOFA can be relatively low in COVID-19 patients on admission, but 
in the aforementioned report some patients in late stage of COVID-19 were transferred to its 
study hospitals7. This might explain the difference in SOFA scores.   
In this study, we aimed to employ routine, widely available clinical test data to predict mortality 
of COVID-19 hospitalised patients using multivariable regression analysis in a cohort of 299 
cases. The model has been established and validated with a new cohort of 145 patients with 
COVID-19 from a different hospital. Through this study, we hope that the experience from the 
outbreak in China will assist the rest of the world in better stratification of COVID-19 patients 
to achieve better outcomes for patients.  
Methods 
Study design and patients  
This was a retrospective observational study performed in officially designated treatment 
centers for confirmed patients with COVID-19 in Wuhan at the center of the outbreak in China. 
The protocol was approved by the local Institutional Ethics Committee (Approval Number: 
KY-2020-10.02). First cohort of 299 patients admitted in Tongji hospital within January and 
February 2020 were enrolled into this study for model development. Second cohort of 151 
patients admitted to Jinyintan hospital who were included in a previous study were reused for 
model validation. All patients were diagnosed by positive tests of novel coronavirus nucleic 
acids (SARS-CoV-2), according to WHO interim guidance8. Only patients who were 
discharged from hospital or had died were included in this study. Six patients in the second 
cohort, who died very quickly after admission and did not received any laboratory testing, were 
excluded. Patients younger than 18 years of age were also excluded.  
Data collection 
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Clinical data, including demographic information, chronic comorbidities, biomarkers of 
infection and other laboratory tests were collected from the local Online Medical System. The 
time from onset of symptoms to hospital admission was also recorded. SOFA was calculated 
within 24h of admission. For patients who did not have arterial blood gas analysis, peripheral 
capillary oxygen saturation (SpO2) to estimate the arterial oxygen partial pressure (PaO2) and 
the recorded fraction of inspired oxygen (FiO2) were used. The SOFA score for the respiratory 
system was calculated according to PaO2/FiO2 (P/F) ratio when patients received non-invasive 
or invasive mechanical ventilation. All patients were closely followed until they died or were 
discharged from the hospital. Hospital mortality and length of hospital stay were also recorded. 
Statistical analysis 
Data were fully anonymized before data cleaning and analyses. We followed the TRIPOD 
guidance for development, validation and reporting of multivariable prediction models6. 
Analyses were performed in R version 3.5.19. The development model was built using the data 
from Tongji Hospital. We performed logistic regression analysis with the outcome variable 
defined as mortality. Variables were selected a priori based on previous clinically-related 
studies, completeness across both sites, clinical knowledge and practicality of measurement in 
acute medical emergencies. Variables were excluded if they had high collinearity with global 
scores. The number of predictors was restricted based on the total number of outcomes in the 
development dataset10. Analysis was conducted for the following nine variables: age, 
hypertension, diabetes, SpO2, systolic blood pressure, albumin, lactate dehydrogenase (LDH), 
lymphocyte count and platelet count. Organ-specific markers, such as alanine transaminase 
(ALT) and blood urea nitrogen (BUN) were not included in the original development model 
because of collinearity with global markers, particularly LDH. SOFA score was not included 
for this reason, as explained in Results. D-dimer, interleukin (IL)-6 and cardiac troponin I (cTnI) 
were excluded from the analysis because they were not routinely tested in the cohorts. LDH 
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was selected as a general marker for cell injury or death and since blood gas analysis were not 
commonly used in these hospitals, SpO2 was selected to reflect respiratory function and was 
modelled as a continuous variable to maximize statistical power11. Albumin was selected as a 
marker for the acute phase response instead of C reactive protein (CRP) because of CRP 
collinearity with LDH. Age is known risk factor for mortality from severe respiratory infections, 
including COVID-19. Lymphocyte count and platelet counts were reported in a previous 
publication of COVID-19 and selected7,12. In this study, lymphocyte count was log transformed 
due to extreme values. Systolic blood pressure (SBP), diabetes and hypertension were selected 
based on previous publications7. All nine selected variables were input into the multivariable 
model and backwards stepwise selection was performed with improvement in goodness-of-fit 
assessed by a reduction in the Akaike Information Criterion (AIC). A nomogram of the selected 
final model was used for graphical representation of the prediction model and was produced 
with R function regplot – this was chosen to offer maximum use of the prediction model in 
clinical practice without the need for internet access13,14.  
Model performance was assessed via measures of discrimination and calibration. To assess 
discrimination, the C statistic was used. For calibration, patients in the development database 
were split into deciles, ordered by their probability of death. For each decile, the mean of the 
predicted probability of death was calculated and compared with the mean observed probability 
of death. Calibration plots were constructed including locally estimated scatterplot smoothing 
(loess) regression lines15.  
Internal validity was assessed with bootstrapping (1000 replications) of the entire model 
building process including backwards stepwise selection of all potential predictors. 
Bootstrapped samples were created by drawing random samples with replacement from the 
development database. The prediction model was fitted on each bootstrap sample and tested on 
the original sample. Overfitting was assessed in each bootstrap replication. This allowed 
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calculation of optimism and optimism adjusted discrimination and calibration statistics. The 
final development model coefficients were then adjusted for optimism using the optimism 
adjusted calibration slope for shrinkage15.  
To assess external validity, the final optimism-adjusted model was applied to an independent 
data set, from Jinyintan hospital. External validity of the model was assessed using the C 
statistic, calibration-in-the-large, calibration slope and the calibration plot. Recalibration was 
conducted updating the intercept, and the intercept and slope. 
Results  
Patient cohorts 
The development cohort included 299 patients who were admitted in Tongji Hospital. Data 
completeness is presented in supplementary Table 1. There were 155 deaths, the median age 
of patients was 65 years (IQR: 54-73) and 48·2% were male (Table 1). The validation cohort 
that included 145 patients was younger: age 56 years (IQR 47-68) with a higher percentage of 
males (65·5%) than in the developmental cohort (P<0·001). The median (IQR) time from onset 
of symptoms to hospital admission was no different in the developmental 10 [7-14] and 
validation 10 [7-13] cohorts. More patients had hypertension (42·6% vs 26·9%) and heart 
failure (4·4% vs 0.7%) in the development than validation cohorts, whilst diabetes (18·5% vs 
11·7%), chronic obstructive pulmonary disease (COPD) (5·0% vs 3·4%) and others (6·4% vs 
4·8) showed no statistical difference. SOFA scores were statistically higher in the development 
than validation cohorts (2·0 [2·0-4·0] vs 1·0 [0·0-3·0]) but both were very low compared to 
common critical illnesses. Table 2 shows that non-survivors were significantly older than 
survivors (69 years (IQR 61·75 to 75·00) vs. 52·50 (IQR 43·75-64·00), p<0·001). Patients with 
hypertension, showed a significantly higher mortality rate (p<0·001).  
Model development 
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In the developmental cohort (Tongji Hospital), 268/299 patients had complete data for all nine 
variables. The final multivariable model included age (adjusted OR 1·054; 95% CI 1·028 to 
1·083), LDH (adjusted OR 1·004; 95% CI 1·002 to 1·006), log lymphocyte count (adjusted 
OR 0·296; 95% CI 0·148 to 0·541) and SpO2 (adjusted OR 0·897; 95% CI 0·831 to 0·958) 
(Table 3). The final model showed excellent discrimination (C statistic = 0·89) and was well 
calibrated (slope =1 and calibration-in-the-large =0·00), as shown in the calibration plot (Table 
4 and Figure 1). The final model for mortality is presented as a nomogram and an example of 
how to use the nomogram is presented for a patient aged 59, with LDH of 482, SpO2 of 85% 
and lymphocyte count of 0·64 (Figure 2). 
Internal validation 
Interval validation was run using bootstrap resampling and showed a small amount of 
overfitting. Bootstrapping with backwards stepwise selection provided a shrinkage factor of 
0.900. After adjusting for overfitting the final model retained high discrimination (C statistic= 
0·880) and calibration-in-the-large of 0·006 (Table 4). The shrinkage factor was applied to the 
β coefficients of the multivariable model to provide optimism adjusted coefficients (Table 3). 
External validation 
External validation is required because the accuracy of a predictive model will always be high 
if it is validated on the development cohort used to generate the model16,17. In this study, we 
applied our final prediction model with optimism adjusted coefficients to the validation dataset. 
There were 145 patients in the validation dataset of whom 69 patients (47·6%) died. Of the 145 
patients, 127 had complete data for the four variables in the final developmental model (age, 
lymphocyte count, SpO2 and LDH) The C statistic for the discrimination of the developed 
model in the independent data was 0·980 (0·958 to 1·000) and the model had reasonable 
calibration (slope and calibration-in-the-large) (Table 5). Figure 3 suggests some mis-
calibration of the model in the independent data with over-estimation of risk of mortality in 
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low-risk individuals and under-estimation of risk in high-risk individuals. After recalibration 
of the intercept, the discrimination of the model was the same (as expected given that 
recalibration does not influence the ranking of individuals according to the model) as was the 
calibration slope. Calibration-in-the-large was 0·00 (-0·477 to 0·471). The calibration plots 
still suggest mis-calibration of the model (Figure 3c). When both intercept and slope were 
recalibrated the calibration slope was 1·00 (0·675 to 1·477) and the plot then demonstrated 
good calibration (Figure 3d). 
Discussion 
Most routine scoring systems, such as SOFA, which are very useful in the intensive care unit 
(ICU) for sepsis and other critical illnesses18-20, were very low in COVID-19 patients on 
admission with median SOFA score of 2. However, 155/299 and 69/145 patients in the 
development and validation cohorts died in the hospital, respectively. This poor outcome 
strongly indicates that these routine scoring systems used in general wards and ICU cannot 
accurately assess the severity and predict the mortality of patients with COVID-19. We have 
therefore used a hospitalized study population from Wuhan Tongji Hospital to develop a 
clinical prediction model using available demographic and clinical indicators. The most 
informative factors in COVID-19 positive patients were age, LDH, lymphocyte count and SpO2. 
The developed statistical model had good discrimination and minimal model optimism. In 
external validation using an independent cohort from Jinyintan hospital, the model had 
excellent discrimination but needed recalibrating to account for the different underlying risk 
profile in the independent dataset. Specifically, the development and validation cohorts are 
temporally distinct as the validation cohort were from earlier in the COVID-19 outbreak. In 
addition, they are from different sites within Wuhan and the demographics are distinct, with 
patients admitted to the Jinyintan hospital being younger with a male majority and less patients 
with hypertension and low SOFA scores (1.0 [0-3] vs 2.0 [2.0-4.0]. However, the nomogram 
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of the final model after optimization can be used by clinicians to give a prediction of mortality 
and thus inform treatment choice and guide patient and family counselling.   
Old age is a major factor of mortality from infection21. This is consistent with the current data 
from China on COVID-19 with less than 1% in children <10 years old, increasing to 2%, 4% 
and 10% in age 11-40, 41-70, and >70, respectively. However, the majority of people infected 
are 30-70 years old (approximately 80% of the total cases), thereby making it difficult to stratify 
the majority of cases according to age. Patient comorbidities, including hypertension, diabetes, 
did not significantly contribute to the model, although mortality rates were significantly higher 
in patients with hypertension.  
The pathological feature of COVID-19 is mainly that of a viral pneumonia with alveolar 
oedema and blockage of small bronchi to compromise gas exchange within the lungs. 
Therefore, PaO2 will drop when severe pneumonia develops. Since arterial blood gas (ABG) 
analysis is an invasive and complex process, which requires arterial blood taking and use of a 
ABG analyzer, SpO2 measurement is much more used for continuous analysis of blood oxygen 
saturation in patients to estimate the arterial oxygen partial pressure (PaO2)
22. Moreover, many 
mobile phone brands contain built-in sensors and SpO2 can be measured by patients themselves. 
In our cohorts, many patients had no blood gas data and therefore SpO2 was used as a variable 
in our model. Although SpO2 is not as accurate as PaO2 in critical illnesses, it could give the 
first indication of compromised lung gas exchange in the early stages of COVID-19, which 
would then be verified by ABG measurement upon admission to hospital.  
Lymphopenia is very common in patients with influenza virus infection and bacterial infection, 
particularly in sepsis23,24. CD4 and CD8 T cell apoptosis causes prolonged infection by 
promoting virus survival25, and induces immune suppression to increase mortality in patients 
with sepsis26. In this study, we found a dramatic difference in lymphocyte counts between 
survivors and non-survivors. In non-survivors, the peripheral lymphocyte counts were very low 
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on admission, indicating that extensive lymphocyte death occurred following infection. LDH 
is released into circulation after cell injury or death27 and serves as an index of the extent of 
cellular damage by the virus or the host immune response28.  
This study has several limitations. At this stage in the global outbreak of COVID-19, no 
published studies have developed and validated prediction models for assessing the probability 
of mortality in hospitalized patients. A most recent report proposed SOFA score, age and D-
dimers as the important prognostic markers7. However, in our cohorts, the SOFA score was 
very low although there is statistical difference between survivors and non-survivors. This 
difference may be due to some patients being treated in other hospitals prior to transfer in the 
previously reported study7. In addition, SOFA score relies on blood gas analysis, which cannot 
be easily done continually, in clinics and in under-resourced settings, thus making it difficult 
for clinicians to use readily. In addition, since D-dimer is not routinely requested, too many 
patients in our cohorts had no test performed, making it is difficult for us to verify published 
results. Organ-specific injury markers were not included in the model, including cTnI due to 
missing data (not routinely measured), as well as ALT and BUN due to high co-linearity with 
other variables within the model. Therefore, the choice of potential prognostic factors could 
not be informed by a systematic review of existing prediction models. Similarly, there are no 
published estimates of discrimination and calibration to compare this study to. Additionally, 
the event rate is limited, especially in the independent dataset where at least 100 events would 
be preferable29. A multicenter study with a larger cohort for model development and also for 
validation would add more power, reduce bias, and make the findings more generically 
applicable.   
There is also inherent bias in the recruitment of patients because the Jinyintan hospital was the 
first officially designated receiving hospital in Wuhan for all COVID-19 cases at the start of 
the outbreak. The recruited patients were mainly self-referrals, but some were referred by other 
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hospitals immediately after a positive diagnostic test. Self-referred patients are more likely to 
have severe symptoms that cause them to seek emergency medical help. Likewise, other 
hospitals are more likely to test patients who have more pronounced symptoms, thus creating 
an inherent bias in the patient sample. Therefore, the cohort may not accurately represent 
patients with mild or asymptomatic COVID-19. These results need to be further validated with 
patients who are hospitalized for different severities of illness. 
Despite these limitations, the obvious advantage of the model developed here is that the panel 
of variables used to build the model are basic demographics and values from accessible clinical 
tests that are recorded routinely in the acute clinical setting. With the vivid nomogram, this 
model will enable the majority of clinicians to assess the severity of patient illness without 
difficulty, particular in very busy clinical settings. We were also able to externally validate our 
model in an independent dataset. The discrimination of the model was high in both internal and 
external validation showing that the model is able to accurately differentiate high and low risk 
individuals. The prediction models are based on and validated in Chinese hospitalized COVID-
19 positive populations and should therefore be applicable to other sites within China and may 
also be translatable into other sites during the global outbreak. However, separate validation 
will be required in other patient populations before widespread application.  
In conclusion, traditional early warning scores and organ injury markers do not help to predict 
severity and mortality in patients with COVID-19. Here, we have developed and validated a 
clinical prediction model using readily available clinical markers which is able to accurately 
predict mortality in people with COVID-19. This model can therefore be used in current 
pandemic regions to identify patients who are at risk of severe disease at an early enough stage 
to initialize intensive supportive treatment and to guide discussions between clinicians, patients 
and families. It has the potential to be used throughout the world following additional validation 
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in relevant worldwide datasets, with recalibration as necessary to account for differing risk 
profiles of patients.  
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Tables 
Table 1: Basic demographics and clinical features of patients in the developmental and validation datasets.  
(For continuous variables median and IQR are reported) 
 
 
Developmental Validation   
 
Tongji (N=299) Jinyintan (N=145) Total (N=444) P value 
Age (Years)     65·0 (54·0, 73·0) 56·0 (47·0, 68·0) 62·0 (50·8, 71·0) < 0·001 
Gender 
   < 0·001 
     Male 144 (48·2%) 95 (65·5%) 239 (53·8%)  
     Female 155 (51·8%) 50 (34·5%) 205 (46·2%)  
Days since onset 10·0 (7·0, 14·0) 10·0 (7·0, 13·0) 10·0 (7·0, 14·0) 0.357 
Co-morbidities 
    
     Hypertension    127 (42·6%) 40 (27·6%) 167 (37·6%) 0·001 
     Diabetes 55 (18·5%) 17 (11·7%) 72 (16·3%) 0·069 
     COPD 15 (5·0%) 5 (3·4%) 20 (4·5%) 0·627 
     Heart Failure 13 (4·4%) 2 (1·4%) 15 (3·4%) 0·042 
     Smoking 10 (3·4%) 7 (4·8%) 17 (3·8%) 0·449 
     Other 19 (6·4%) 7 (4·8%) 26 (5·9%) 0·515 
Mortality, n (%) 155 (51·8%) 69 (47·6%) 224 (50·5%) 0·419 
SPO2, (%) 
95·0 (90·0, 98·0) 95·0 (89·0, 97·0) 95·0 (90·0, 98·0) 0·366 
SPO2, (%) 
   0·340 
     ≥90 229 (77·4%) 95 (73·1%) 324 (76·1%)  
     <90 67 (22·6%) 35 (26·9%) 102 (23·9%)  




132·5 (118·0, 145·0) 122·5 (117·0, 137·3) 129·5 (117·0, 143·0) 0·008 
WBC, 109/L 6·8 (4·7, 10·6) 7·6 (5·0, 11·2) 6·9 (4·8, 10·8) 0·562 
Lymphocyte count, 
109/L 
0·75 (0·50, 1·11) 0·74 (0·52, 1·13) 0·75 (0·50, 1·12) 0·703 
Platelet count, 109/L 179·5 (137·3, 247·8) 192·0 (140·5, 242·3) 182·0 (138·0, 247·3) 0·413 
D-dimer, mg/L    0·274 
     <0.5 49 (19·0%) 36 (25·9%) 85 (21·4%)  
     0.5-1.0 55 (21·3%) 28 (20·1%) 83 (20·9%)  
     ≥1.0 154 (59·7%) 75 (54·0%) 229 (57·7%)  
Albumin, g/L 33·4 (29·9, 36·2) 30·7 (27·4, 34·5) 32·5 (28·9, 35·8) < 0·001 
hs-cTnI, pg/ml    0·198 
     <28.0 173 (71·5%) 107 (77·5%) 280 (73·7%)  
     ≥28.0 69 (28·5%) 31 (22·5%) 100 (26·3%)  
ALT, U/L 26·0 (16·0, 40·8) 29·0 (19·0, 51·0) 27·0 (17·0, 45·0) 0·017 
AST, U/L 33·5 (24·0, 56·0) 36·0 (27·0, 47·5) 34·0 (25·0, 53·0) 0·400 
Bilirubin, mol/L         10·3 (7·6, 14·6) 12·5 (9·7, 17·4) 11·4 (8·2, 15·9) <0.001· 
BUN, mmol/L 5·9 (3·9, 9·2) 5·8 (4·4, 7·6) 5·9 (4·1, 8·6) 0·602 
Creatinine, U/L      74·0 (58·0, 95·0) 72·9 (58·8, 84·6) 73·2 (58·5, 93·0) 0·264 
Creatinine kinase, 
U/L  
131·0 (70·0, 380·8) 92·0 (52·0, 183·0) 101·0 (58·0, 238·0) 0·005 
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LDH, U/L  384·0 (264·0, 541·0) 333·0 (251·0, 521·0) 362·0 (260·5, 535·3) 0·199 
CRP, mg/dl 65·3 (27·4, 113·9) 58·3 (23·7, 114·5) 64·5 (25·1, 114·4) 0·442 
INR, s 1·13 (1·04, 1·25) 0·96 (0·90, 1·03) 1·07 (0·98, 1·18) <0·001 
Procalcitonin, ng/ml 0·13 (0·05, 0·37) 0·07 (0·05, 0·19) 0·10 (0·05, 0·27) 0·030 
 
Data are presented as median (IQR), or n (%). P values were calculated using Wilcoxon rank-sum test, χ2 or Fisher’s exact test. 
ALT= Alanine aminotransferase. AST= Aspartate aminotransferase. BUN=Blood urea nitrogen. COPD=chronic obstructive 
disease. CRP= C-reactive protein. hs-cTnI= high-sensitivity cardiac troponin I. INR= international normalized ratio. LDH= 
lactate dehydrogenase. SOFA= sequential organ failure assessment. SPO2= pulse oxygen saturation. WBC=white blood cell. 
 
Table 2: Differences in demographics between COVID-19 patients who survived and died in developmental and 
validation datasets. (For continuous variables median and IQR are reported) 
 
 Developmental (Tongji) Validation (Jinyintan) 
  Survived (N=144) Died (N=155) P value Survived (N=76) Died (N=69) P value 
Age (Years)     56·0 (47·8, 67·0) 69·00 (62·0, 76·0) <0·001 47·0 (40·8, 53·3) 67·0 (61·0, 73·0) < 0·001 
Gender   0·191   0·673 
     Male 75 (52·1%) 69 (44·5%)  51 (67·1%) 44 (63·8%)  
     Female 69 (47·9%) 86 (55·5%)  25 (32·9%) 25 (36·2%)  
Days since 
onset 
10·0 (7·0, 13·0) 10·0 (7·0, 15·0) 0·267 9·0 (7·0, 12·3) 10·0 (7·0, 13·0) 0·062 
Co-morbidities       
     
Hypertension    
47 (32·6%) 80 (51·9%) <0·001 8 (10·5%) 31 (44·9%) <0·001 
     Diabetes 21 (14·6%) 34 (22·2%) 0·09 4 (5·3%) 13 (18·8%) 0·018 
     COPD 2 (1·4%) 13 (8·4%) 0·006 1 (1·3%) 4 (5·8%) 0·192 
     Heart 
Failure 
1 (0·7%) 12 (7·8%) 0·003 0 (0·0%) 1 (1·4%) 0·476 
     Smoking 5 (3·5%) 5 (3·2%) 0·914 1 (1·3%) 6 (8·7%) 0·054 
     Other 8 (5·6%) 11 (7·1%) 0·575 2 (2·6%) 5 (7·2%) 0·258 
SpO2, (%) 
97·0 (95·0, 98·0) 92·0 (83·8, 96·0) <0·001 97·0 (94·8, 98·0) 89·0 (81·0, 94·0) < 0·001 
SpO2, (%) 
  <0·001   < 0·001 
     ≥90 136 (94·4%) 93 (61·29%)  68 (94·4%) 27 (46·6%)  
     <90 8 (5·6%) 59 (38·8%)  4 (5·6%) 31 (53·4%)  













WBC, 109/L 5·4 (4·0, 7·2) 9·0 (5·9, 13·4) <0·001 5·6 (3·5, 8·8) 8·7 (6·7, 12·5) < 0·001 
Lymphocyte 
count, 109/L 













D-dimer, mg/L   <0·001   <0·001 
     <0.5 39 (32·0%) 10 (7·4%)  33 (45·2%) 3 (4·5%)  
     0.5-1.0 37 (30·3%) 18 (13·2%)  18 (24·7%) 10 (15·2%)  
     ≥ 1.0 46 (37·7%) 108 (79·4%)  22 (30·1%) 53 (80·3%)  
Albumin g/L 35·6 (32·7, 37·9) 31·3 (28·2, 34·3) <0·001 33·8 (30·7, 35·7) 28·5 (25·8, 30·4) <0·001 
cTnI, pg/ml   <0·001   <0·001 
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     <28.0 104 (96·3%) 69 (51·5%)  70 (98·6%) 37 (55·2%)  
     ≥28.0 4 (3·7%) 65 (48·5%)  1 (1·4%) 30 (44·8%)  
ALT, U/L 23·0 (15·0, 37·0) 28·0 (19·0, 44·0) 0·026 26·5 (18·0, 40·3) 41·0 (20·5, 55·5) 0·024 
AST, U/L 30·0 (21·5, 44·0) 42·0 (26·0, 64·0) <0.001 31·0 (25·8, 39·0) 42·0 (34·5, 59·5) <0.001 
Bilirubin, 
mol/L                
8·4 (6·5, 11·9) 12·7 (9·0, 18·8) <0·001 11·5 (9·1, 13·8) 15·7 (11·6, 22·6) <0·001 
BUN, mmol/L 4·4 (3·3, 6·0) 8·0 (5·7, 11·9) <0·001 4·6 (3·7, 5·8) 7·5 (6·2, 8·9) <0·001 
Creatinine, U/L      66·0 (56·0, 83·0) 85·0 (66·0, 109·0) <0·001 71·8 (57·6, 82·1) 74·4 (64·6, 92·1) 0·180 
Creatinine 
kinase, U/L      
90·5 (38·9, 383·8) 137·0 (78·0, 381) 0.052 76·5 (46·8, 144·3) 99·0 (58·0, 196) 0·052 
LDH, U/L     295 (216, 388) 505(371, 676) <0·001 264 (214, 319) 531 (413, 637) <0·001 
CRP, mg/dl 39·0 (10·7, 80·6) 97·2 (47·2, 148·8) <0.001 26·4 (7·5, 61·8) 112·1 (65·4, 160) <0·001 
INR, s 1·08 (1·02, 1·16) 1·20 (1·08, 1·38) <0.001 0·92 (0·86, 0·99) 1·01 (0·94, 1·10) <0.001 
Data are presented as median (IQR), or n (%). P values were calculated using Wilcoxon rank-sum test, χ2 or Fisher’s exact test. ALT= 
Alanine aminotransferase. AST= Aspartate aminotransferase. BUN=Blood urea nitrogen. COPD=chronic obstructive disease. CRP= 
C-reactive protein. hs-cTnI= high-sensitivity cardiac troponin I. INR= international normalized ratio. LDH= lactate dehydrogenase. 
SOFA= sequential organ failure assessment. SPO2= pulse oxygen saturation. WBC=white blood cell. 
 
Table 3: Final multivariable model in development dataset and optimism adjusted β coefficients 
 Development model Final model with 
shrinkage 
 
Variable β Coefficients (95% CI) Odds ratio (95% CI) Optimism adjusted β 
coefficients 
Age 0·053 (0·027 to 0·08) 1·054 (1·028 to 1·083) 0·047 
LDH 0·004 (0·002 to 0·006) 1·004 (1·002 to 1·006) 0·003 
Lymphocyte count -1·216 (-1·910 to -0·614) 0·296 (0·148 to 0·541) -1·094 
SPO2 -0·109 (-0·186 to -0·043) 0·897 (0·831 to 0·958) -0·098 
Intercept 5·068 (-1·797 to 12·737)  4·559 
  
 
Table 4. Internal validation: model performance 
Measure Development model Average optimism Optimism adjusted 
C statistic 0·893 (0·856 to 0·930) 0·013 0·880 
Calibration in the large 0·000 (-0·331 to 0·330) -0·006 0·006 
Calibration Slope 1·000 (0·773 to 1·264)) 0·100 0·900 
 
 








(intercept and slope) 
C statistic 0·980 (0·958 to 
1·000) 
0·980 (0·958 to 
1·000) 
0·980 (0·958 to 
1·000) 
0·980 (0·958 to 
1·000) 
Calibration in the 
large 
-0·192 (-0·690 to 
0·300) 
-0·195 (-0·673 to 
0·276) 
0·000 (-0·477 to 
0·471) 
0·000 (-0·725 to 
0·738) 
Calibration Slope 2·227 (1·503 to 
3·291) 
2·476 (1·671 to 
3·658) 
2·476 (1·671 to 
3·658) 
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   Figure 1 Calibration plot of the final development model. 
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Figure 2 Nomogram of the final development model. The nomogram presents the distribution of continuous 
variables and for categorical variables the relative contribution of variable to the model is reflected in the size. 
The distribution of the final score is shown for the development data and the red dots represent a randomly selected 
patient from the development dataset with probability of mortality of 0.77. 
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Figure 3. Calibration plots of external validation. A) Calibration without shrinkage B) Calibration with 
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